Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Vildagliptin and Metformin Improve Glycemic Control in Type 2 Diabetes
Last updated July 22, 2026
Key finding
FBG decreased significantly from baseline to 6 months (p < 0.001).
This study investigated the effects of Vildagliptin and Metformin on hepatic steatosis in newly diagnosed Type 2 diabetes patients, showing significant improvements in various metabolic parameters.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of Vildagliptin and Metformin on hepatic steatosis in newly diagnosed Type 2 diabetes patients, showing significant improvements in various metabolic parameters.
Clinical relevance
These findings are clinically significant as they suggest that Vildagliptin and Metformin not only help control blood sugar levels but also contribute to weight loss and reduced liver fat, which are critical factors in managing Type 2 diabetes and preventing its complications.
Keep in mind
Study may have limited generalizability due to specific population characteristics. Lack of long-term follow-up data to assess sustained effects. No significant difference in ultrasound grading of hepatic steatosis between groups.
Published in
Journal Reference
Publication details and source links for this paper.
Asmaa SM, Hosam MA, Mohammed AS, Fatma MMK. Effects of Vildagliptin and Metformin on Hepatic Steatosis in Newly Diagnosed Type 2 Diabetes Patients. BMC Pharmacology & Toxicology. 2024;25:94. doi:10.1186/s40360-024-00818-7
Main Effects
Fasting Blood Glucose decreased by 110.62 mg/dL (p < 0.001)
HbA1c decreased by 1.74% (p < 0.001)
Body weight decreased by 5.79 kg (p < 0.001)
Hepatic Steatosis Index decreased significantly (p < 0.001)
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dipeptidyl peptidase-4 inhibitors, Metformin and BMI, Body weight, Change in Hepatic Steatosis Index (HSI), and 5 more.
This study contributes evidence to
Primary intervention
Dipeptidyl peptidase-4 inhibitors
Primary outcomes
- BMI
- Body weight
- Change in Hepatic Steatosis Index (HSI)
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
16
Evidence pairs
16
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
5
Related topics
16
Evidence pairs
774
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 16 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
DPP-4 Inhibitors and HbA1c
Related evidence
Evidence relationship
Metformin Therapies and Fasting Glucose
Save evidence
Evidence relationship
Metformin Therapies and HbA1c
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Body weight
Dipeptidyl peptidase-4 inhibitors → Body weight
Dipeptidyl peptidase-4 inhibitors → Body weight
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerChange in Hepatic Steatosis Index (HSI)
Dipeptidyl peptidase-4 inhibitors → Change in Hepatic Steatosis Index (HSI)
Dipeptidyl peptidase-4 inhibitors → Change in Hepatic Steatosis Index (HSI)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerFasting blood sugar (FBS)
Dipeptidyl peptidase-4 inhibitors → Fasting blood sugar (FBS)
Dipeptidyl peptidase-4 inhibitors → Fasting blood sugar (FBS)
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerHip circumference
Dipeptidyl peptidase-4 inhibitors → Hip circumference
Dipeptidyl peptidase-4 inhibitors → Hip circumference
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerUltrasound Grading of Hepatic Steatosis
Dipeptidyl peptidase-4 inhibitors → Ultrasound Grading of Hepatic Steatosis
Dipeptidyl peptidase-4 inhibitors → Ultrasound Grading of Hepatic Steatosis
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerWaist circumference
Dipeptidyl peptidase-4 inhibitors → Waist circumference
Dipeptidyl peptidase-4 inhibitors → Waist circumference
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerChange in Hepatic Steatosis Index (HSI)
Metformin → Change in Hepatic Steatosis Index (HSI)
Metformin → Change in Hepatic Steatosis Index (HSI)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 11 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerUltrasound Grading of Hepatic Steatosis
Metformin → Ultrasound Grading of Hepatic Steatosis
Metformin → Ultrasound Grading of Hepatic Steatosis
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- FBG levels decreased significantly by 110.62 mg/dL.
- HbA1c levels reduced by 1.74%, indicating improved glucose control.
- Body weight decreased by an average of 5.79 kg, suggesting effective weight management.
Who this applies to
- Adults newly diagnosed with Type 2 diabetes.
- Patients seeking pharmacological management for diabetes.
Keep in Mind
- Results may not apply to populations outside the study's demographic.
- Short duration of the study limits understanding of long-term effects.
- Further research is needed to explore the impact on hepatic steatosis via imaging.
Between the Lines
- Study may have limited generalizability due to specific population characteristics.
- Lack of long-term follow-up data to assess sustained effects.
- No significant difference in ultrasound grading of hepatic steatosis between groups.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and HbA1c, DPP-4 Inhibitors and Body Weight.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Metformin Therapies → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 11 studies
View evidenceMedications
DPP-4 Inhibitors → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
11 studies
intervention_hubContributes to Metformin Therapies evidence base.
Body Weight Evidence Hub
All studies measuring Body Weight
3 studies
outcome_hubMeasures Body Weight as a key outcome.
DPP-4 Inhibitors Evidence Hub
All studies on DPP-4 Inhibitors
3 studies
intervention_hubContributes to DPP-4 Inhibitors evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Metformin and HbA1c
Intervention: MetforminOutcome: HbA1c
11 results
All studies on Dipeptidyl peptidase-4 inhibitors and Body weight
Intervention: Dipeptidyl peptidase-4 inhibitorsOutcome: Body weight
3 results
All studies on Metformin
Intervention: Metformin
11 results
All studies on Dipeptidyl peptidase-4 inhibitors
Intervention: Dipeptidyl peptidase-4 inhibitors
3 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does DPP-4 Inhibitors improve HbA1c?
Strong Evidence
DPP-4 Inhibitors appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve fasting glucose?
Strong Evidence
Metformin Therapies may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Fasting blood sugar (FBS)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve HbA1c?
Strong Evidence
Metformin Therapies appears to improve HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.2 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies affect body mass index?
Strong Evidence
Metformin Therapies appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Sitagliptin with Metformin Improves Metabolic HealthDietary interventions improve glycemic control in pre-diabetic patientsMediterranean ketogenic eating matched VLCKD for weight loss over 3 monthsSemaglutide improves vascular and liver function in type 2 diabetesVildagliptin improves post-meal glucose control during Ramadan fasting
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.